<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10596256
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0890-8567
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       38
      </volume>
      <issue>
       12
      </issue>
      <pubdate>
       <year>
        1999
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of the American Academy of Child and Adolescent Psychiatry
     </title>
     <isoabbreviation>
      J Am Acad Child Adolesc Psychiatry
     </isoabbreviation>
    </journal>
    <articletitle>
     A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.
    </articletitle>
    <pagination>
     <medlinepgn>
      1551-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Meta-analysis was used to review the literature on the clinical use of clonidine to treat symptoms of attention-deficit hyperactivity disorder (ADHD).
     </abstracttext>
     <abstracttext label="METHOD" nlmcategory="METHODS">
      A review of the literature from 1980 to 1999 revealed 39 studies that reported clonidine's efficacy and side effects for symptoms of ADHD and comorbid conditions. Of these, 11 reports provided sufficient information to be included in a meta-analysis.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Meta-analysis using weighted variables revealed clonidine demonstrates a moderate effect size of 0.58 +/- 0.16 (95% confidence interval = 0.27-0.89) on symptoms of ADHD in children and adolescents with ADHD and ADHD comorbid with conduct disorder, developmental delay, and tic disorders.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Clonidine may be an effective second-tier treatment for symptoms of ADHD, but it has an effect size less than that of stimulants. Clinical use of clonidine is associated with many side effects.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Psychiatry, University of Massachusetts Medical School, Worcester 01655, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Connor
      </lastname>
      <forename>
       D F
      </forename>
      <initials>
       DF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fletcher
      </lastname>
      <forename>
       K E
      </forename>
      <initials>
       KE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Swanson
      </lastname>
      <forename>
       J M
      </forename>
      <initials>
       JM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Meta-Analysis
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Am Acad Child Adolesc Psychiatry
    </medlineta>
    <nlmuniqueid>
     8704565
    </nlmuniqueid>
    <issnlinking>
     0890-8567
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic alpha-Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      4205-90-7
     </registrynumber>
     <nameofsubstance>
      Clonidine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic alpha-Agonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Attention Deficit Disorder with Hyperactivity
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child Behavior Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clonidine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Impulsive Behavior
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Psychiatric Status Rating Scales
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Psychomotor Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1999
     </year>
     <month>
      12
     </month>
     <day>
      22
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1999
     </year>
     <month>
      12
     </month>
     <day>
      22
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1999
     </year>
     <month>
      12
     </month>
     <day>
      22
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10596256
    </articleid>
    <articleid idtype="pii">
     S0890-8567(09)66720-4
    </articleid>
    <articleid idtype="doi">
     10.1097/00004583-199912000-00017
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

